PATENT CLAIM ANALYSIS

Application Number: 16125991
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "380000"]

Abstract:
In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I′) forms.

Claim (Index 39):
The crystalline form of  claim 17 ,  20  or  22 , wherein the crystalline form is characterized by having one or more additional diffraction peaks at 2\u03b8 values selected from 6.51\u00b10.20, 11.62\u00b10.20, 13.05\u00b10.20, 15.07\u00b10.20, 15.72\u00b10.20, 17.12\u00b10.20, 20.79\u00b10.20, 21.10\u00b10.20, 23.28\u00b10.20, 24.48\u00b10.20, 25.81\u00b10.20, and 26.19\u00b10.20.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 97.0
- Lexical Diversity: 1.65116
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15452333', '15040481', '15042391', '14812095', '13767285']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7702924380005389
- 35 USC 102 Novelty (BERT): 0.5559070638737171
- Combined Prediction Score: 0.7488539005878568
- Mean Citation Score: 324.98591
- Max Citation Score: 400.483
- Similarity Product: 373.2718947117328

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test